The ethnomedicinal values of plants form the basis of the herbal drug industry. India has contributed its knowledge of traditional system medicines (Ayurveda and Siddha) to develop herbal medicines with negligible side effects. The World Health Organization has also recognized the benefits of drugs developed from natural products. Abutilon indicum, Hibiscus sabdariffa, Sida acuta and Sida rhombifolia are ethnomedicinal plants of Malvaceae, commonly used in Indian traditional system of medicines. Traditionally these plants were used in the form of extracts/powder/paste by tribal populations of India for treating common ailments like cough and cold, fever, stomach, kidney and liver disorders, pains, inflammations, wounds, etc. The present review is an overview of phytochemistry and ethnopharmacological studies that support many of the traditional ethnomedicinal uses of these plants. Many phytoconstituents have been isolated from the four ethnomedicinal plants and some of them have shown pharmacological activities that have been demonstrated by in vivo and/or in vitro experiments. Ethnomedicinal uses, supported by scientific evidences is essential for ensuring safe and effective utilization of herbal medicines.

The genusPhyllanthusconsists of more than 1000 species, of which many are used as traditional medicines. The plant extracts have been used since ancient times, for treating hypertension, diabetes, hepatic, urinary, and sexual disorders, and other common ailments. Modern day scientific investigations have now confirmed pharmacognostic properties ofPhyllanthusherbs. The phytochemicals attributing these medicinal properties have been identified in many of thePhyllanthusherbs. The morphologically similar herbs ofPhyllanthusgrow together and admixture of species during collection for manufacture of herbal medicines is quite common. Hence, along with pharmacognostic and phytochemical studies, appropriate protocols for correct identification of species are also important. As the use of these herbs as green medicines is becoming more popular, it is imperative to assess its genetic diversity and phylogenetic relatedness for future conservation strategies. This review is an attempt to present an overview of the existing studies on pharmacognostics, phytochemistry, species identification, and genetic diversity ofPhyllanthusherbs and consequently (i) highlight areas where further research is needed and (ii) draw attention towards extending similar studies in underutilized but potentially important herbs such asP. maderaspatensis,P. kozhikodianus,P.rheedii,P. scabrifolius,andP. rotundifolius.

Ulmus glabra Hudson, or Wych elm, occurs as fragmented and relict natural populations in the Central System, which acts as a refugium in the Iberian Peninsula. Considering the importance of the Central System populations of U. glabra, the main objective was to assess their genetic diversity using nuclear microsatellite markers. A total of 360 different genotypes were detected in the 427 U. glabra individuals analyzed. Wych elm populations showed a highly significant genetic differentiation (24%; p = 0.0001). Of the 22 populations studied, population of Rozas de Puerto Real (ROZ) showed the highest values of effective number of alleles (2.803), mean Shannon’s diversity (1.047) and expected heterozygosity (0.590). Populations of ROZ and Mombeltrán (MOM) showed the highest values of observed heterozygosity (0.838 and 0.709, respectively), and highly negative values for inbreeding coefficient (−0.412 and −0.575, respectively). Also, most of putative hybrids (50 of 55) were observed in these two populations. Demographic analysis revealed signals for recent (four populations) and ancestral (fifteen populations) bottlenecks. Fragmented populations with diminishing number of individuals, along with anthropogenic intervention and Dutch elm disease (DED), are the main threats to U. glabra populations. From a future perspective, the information generated can be considered in the formulation of conservation strategies for U. glabra populations in the Central System.

Enzyme prodrug therapy has gained momentum in recent years due to its ability to improve therapeutic index (benefits versus toxic side-effects) and efficacy of chemotherapy in cancer treatment. Inactive prodrugs used in this system are converted into active anti-cancerous drugs by enzymes, specifically within the tumor cells. This therapy involves three components namely prodrug, enzyme and gene delivery vector. Past reports have clearly indicated that the choice of enzyme used is the major determinant for the success of this therapy. Generally, enzymes from nonhuman sources are employed to avoid off-target toxicity. Exogenous enzymes also give better control to the clinician regarding the calibration of treatment by site-specific initiation. Amongst these exo-enzymes, microbial enzymes are preferred due to their high productivity, stability and ease of manipulation. The present review focuses on the commonly used microbial enzymes, particularly cytosine deaminase, nitroreductase, carboxypeptidase, purine nucleoside phosphorylase in prodrug activation therapy. Various aspects viz. source of the enzymes, types of cancer targeted, mode of action and efficacy of the enzyme/prodrug system, efficient vectors used and recent research developments of each of these enzymes are comprehensively elaborated. Further, the results of the clinical trials and various strategies to improve their clinical applicability are also discussed.